Baseline dasabuvir resistance in Hepatitis C virus from the genotypes 1, 2 and 3 and modeling of the NS5B-dasabuvir complex by the in silico approach

Background: Current combination treatments with direct-acting antiviral agents (DAAs) can cure more than 95% of hepatitis C virus (HCV) infections. However, resistance-associated substitutions (RASs) may emerge and can also be present in treatment-naïve patients. Methods, results and discussion: In...

Descripción completa

Detalles Bibliográficos
Autores principales: Akaberi, Dario, Bergfors, Assar, Kjellin, Midori, Kameli, Nader, Lidemalm, Louise, Kolli, Bhavya, Shafer, Robert W., Palanisamy, Navaneethan, Lennerstrand, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179053/
https://www.ncbi.nlm.nih.gov/pubmed/30319736
http://dx.doi.org/10.1080/20008686.2018.1528117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6179053/
https://www.ncbi.nlm.nih.gov/pubmed/30319736
http://dx.doi.org/10.1080/20008686.2018.1528117

Ejemplares similares